Bill Sbiliris, MD
Psychiatry · Glendale, AZNPI 1710017355
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.0%), food and beverage and education — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 79.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $4,580 and has fallen 89.5% since, to $481 in 2025. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $81.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$5K
- Janssen Scientific Affairs, LLC$367
- E.r. Squibb & Sons, L.L.C.$300
- Johnson & Johnson$222
- Indivior Inc.$166
- AbbVie$147
- plus $218 from 3 others
What the payments were for
- Speaking & faculty fees$3,74055%
- Food & beverage$2,97444%
- Education$921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 53 | $5,385 |
| Janssen Scientific Affairs, LLC | 3 | $367 |
| E.r. Squibb & Sons, L.L.C. | 6 | $300 |
| Johnson & Johnson | 8 | $222 |
| Indivior Inc. | 8 | $166 |
| AbbVie | 2 | $147 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$3,861
- VIVITROL$3,740
- ARISTADA INITIO$965
- INVEGA SUSTENNA$277
- COBENFY$245
- INVEGA TRINZA$142
- SPRAVATO$139
- VRAYLAR$132
- INGREZZA$125
How this compares
$6,806 in reported general payments places this provider in the 90th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine OdtOlanzapine | 13 | $800 |
| Clozapine | 11 | $316 |
| Hydroxyzine Pamoate | 41 | $264 |
| Gabapentin | 22 | $155 |
| Quetiapine Fumarate | 17 | $153 |
| Trazodone Hcl | 19 | $90 |
| Risperidone | 13 | $85 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Glendale
- Jasbir BislaGlendale$12K
- Carl SonderGlendale$8K
- Patricia KirbyGlendale$7K
- Satinder PurewalGlendale$6K
- Tyler VestalGlendale$5K
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Bahar GolestanMesa$234K
- Eric ReimanPhoenix$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.